Intervacc AB
2E9
Company Profile
Business description
Intervacc AB is a biotechnology company. It develops new vaccines based on recombinant proteins to meet the increasing need for effective vaccines in animal health care. The company through its subsidiary focuses on diagnostics in the Swedish animal health market and offers bacteriological and mycological analyses on the Swedish market.
Contact
Vastertorpsvagen 135
Hagersten
StockholmS-129 44
SWET: +46 812010600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
15
Stocks News & Analysis
stocks
Strong results from cheap ASX share
The market responded favourably to results but shares still underpriced.
stocks
Anthropic’s Claude code security release is not bad news for cyber stocks
We believe cyber vendors will be able to adopt LLM’s for their benefit.
stocks
Earnings losers: TWE, GMG, SUN and more fall on weaker profits
Where companies fell short of market expectations in the third week of earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,244.60 | 16.20 | -0.17% |
| CAC 40 | 8,497.17 | 18.32 | -0.22% |
| DAX 40 | 24,991.97 | 268.72 | -1.06% |
| Dow JONES (US) | 48,804.06 | 821.91 | -1.66% |
| FTSE 100 | 10,684.74 | 2.15 | -0.02% |
| HKSE | 26,527.74 | 554.17 | -2.05% |
| NASDAQ | 22,627.27 | 258.79 | -1.13% |
| Nikkei 225 | 57,320.42 | 494.72 | 0.87% |
| NZX 50 Index | 13,511.10 | 90.67 | 0.68% |
| S&P 500 | 6,837.75 | 71.76 | -1.04% |
| S&P/ASX 200 | 9,022.50 | 11.90 | -0.13% |
| SSE Composite Index | 4,129.78 | 47.71 | 1.17% |